709 related articles for article (PubMed ID: 7522954)
1. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
3. Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Cassatella MA; Trentin L; Bulian P; Siviero F; Feruglio C; Agostini C; Vespignani M; Chisesi T; Pizzolo G
Leukemia; 1991 Nov; 5(11):942-50. PubMed ID: 1835747
[TBL] [Abstract][Full Text] [Related]
4. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
5. Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation.
Comoli P; Maccario R; Montagna D; Labirio M; Zecca M; Clementi R; Bonetti F; Locatelli F
Clin Exp Immunol; 1994 Sep; 97(3):510-6. PubMed ID: 8082308
[TBL] [Abstract][Full Text] [Related]
6. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
7. Functional p75 interleukin-2 receptor expression on the fresh blast cells in childhood acute lymphoblastic leukemia with natural killer cell properties.
Ichikawa M; Kawai H; Komiyama A; Tsudo M; Miyasaka M; Kinoshita A; Nakazawa S
Am J Hematol; 1991 Apr; 36(4):259-64. PubMed ID: 2012073
[TBL] [Abstract][Full Text] [Related]
8. Low-dose interleukin-2 in combination with interferon-alpha effectively modulates biological response in vivo.
Schneekloth C; Körfer A; Hadam M; Lopez Hänninen E; Menzel T; Schomburg A; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Acta Haematol; 1993; 89(1):13-21. PubMed ID: 7683166
[TBL] [Abstract][Full Text] [Related]
9. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
10. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
[TBL] [Abstract][Full Text] [Related]
11. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
12. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.
Foxwell BM; Simon J; Herrero JJ; Taylor D; Woerly G; Cantrell D; Ryffel B
Immunology; 1990 Jan; 69(1):104-9. PubMed ID: 2312149
[TBL] [Abstract][Full Text] [Related]
14. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
[TBL] [Abstract][Full Text] [Related]
15. Phorbol myristate acetate-induced expression of high-affinity interleukin 2 receptors and production of interleukin 2 by human acute lymphoblastic leukemia T cells.
Sahraoui Y; Allouche M; Perrakis M; Clemenceau C; Jasmin C; Georgoulias V
Leukemia; 1992 Apr; 6(4):295-303. PubMed ID: 1588792
[TBL] [Abstract][Full Text] [Related]
16. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
17. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
18. Cell membrane expression and functional role of the p75 subunit of interleukin-2 receptor in lymphoproliferative disease of granular lymphocytes.
Zambello R; Trentin L; Pizzolo G; Bulian P; Masciarelli M; Feruglio C; Agostini C; Raimondi R; Chisesi T; Semenzato G
Blood; 1990 Nov; 76(10):2080-5. PubMed ID: 2146981
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]